Intravitreal Brolucizumab in a Sentence

Manuscript Generator

Learn more from Intravitreal Brolucizumab

More Intravitreal Brolucizumab sentence examples

10.1016/j.pdpdt.2021.102450

The patient was shifted to intravitreal Brolucizumab.

A case of recalcitrant neovascular wet age-related macular degeneration treated with Intravitreal Brolucizumab.

10.1038/s41433-021-01816-3

All patients were treated with intravitreal brolucizumab 6mg between November 2020 and May 2021.

Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema

10.1007/s00347-021-01474-6

CONCLUSION Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment.

[Real-life experiences with Brolucizumab in recalcitrant neovascular age-related macular degeneration].

Discover more insights into Intravitreal Brolucizumab

Keywords frequently search together with Intravitreal Brolucizumab

Narrow sentence examples with built-in keyword filters

10.1097/MD.0000000000027580

Interventions: A combination therapy involving of intravitreal brolucizumab and STTA Outcomes: The anti-vascular endothelial growth factor inhibitor was changed back to aflibercept; however, exudation persisted.

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation

10.3390/biomedicines9091164

Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14).

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy

10.1159/000518809

Although the serous retinal detachment (SRD) disappeared after IVA treatment, the patient was managed with treatment every 4 weeks without extending the treatment interval To shorten the treatment interval, intravitreal brolucizumab (IVBr) was started 44 weeks after starting IVA treatment.

Vitreous Noise on Optical Coherence Tomography as an Early Finding of Brolucizumab-Related Intraocular Inflammation

10.1007/s40278-021-96858-z

Recently, she had been switched to intravitreal brolucizumab injection.

Difluprednate/methylprednisolone/monoclonal-antibodies

Learn more from Intravitreal Brolucizumab

An Overview of Intravitreal Brolucizumab

Intravitreal Brolucizumab
Encyclopedia

What is/are Intravitreal Brolucizumab?

Intravitreal Brolucizumab - The patient was shifted to intravitreal Brolucizumab. [1] All patients were treated with intravitreal brolucizumab 6mg between November 2020 and May 2021. [2] CONCLUSION Intravitreal brolucizumab treatment can achieve significant reductions particularly of SRF and sub-RPE in patients refractory to previous anti-VEGF treatment. [3] Interventions: A combination therapy involving of intravitreal brolucizumab and STTA Outcomes: The anti-vascular endothelial growth factor inhibitor was changed back to aflibercept; however, exudation persisted. [4] Patients received 3 monthly intravitreal aflibercept (n = 38) or intravitreal brolucizumab (n = 14). [5] Although the serous retinal detachment (SRD) disappeared after IVA treatment, the patient was managed with treatment every 4 weeks without extending the treatment interval To shorten the treatment interval, intravitreal brolucizumab (IVBr) was started 44 weeks after starting IVA treatment. [6] Recently, she had been switched to intravitreal brolucizumab injection. [7]

neovascular age related

Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] We evaluated the efficacy and safety of loading phase treatment with intravitreal brolucizumab for neovascular age-related macular degeneration (nAMD) with type 1 choroidal neovascularization (CNV). [2] The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [3] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [4] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [5]

Received Intravitreal Brolucizumab

All patients received intravitreal brolucizumab as primary or switch therapy. [1] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [2]

intravitreal brolucizumab injection

Case 2: An 82-year-old man who had neovascular age-related macular degeneration, received the first dose of intravitreal brolucizumab injection OD. [1] Purpose To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. [2] Recently, she had been switched to intravitreal brolucizumab injection. [3] To describe three Japanese cases of retinal vasculitis that occurred following intravitreal brolucizumab injections and the systemic and local steroid treatment administered. [4] The woman with a known medical history of an allergy to tropicamide ophthalmic solution, received intravitreal brolucizumab injection for polypoidal choroidal vasculopathy OD. [5]

intravitreal brolucizumab therapy

The aim of the present study was to determine the efficacy and safety of intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) in the real-world setting. [1] The present study aimed to determine the efficacy and safety of pro re nata (PRN) intravitreal brolucizumab therapy for neovascular age-related macular degeneration (AMD) without a loading dose in the real-world setting. [2]